Changes in the business of culture

Nature Biotechnology

Volumn 22, Issue 11, 2004, Pages 1355-1356

  De Noronha Pissarra, Pedro ^a  

^a Biotecnol SA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ERYTHROPOIETIN; GENERIC DRUG; GRANULOCYTE COLONY STIMULATING FACTOR; HEPATITIS B VACCINE; PEPTIDE; RECOMBINANT PROTEIN; STREPTOKINASE;

BIOCHEMISTRY; CELL CULTURE; CELL LINE; CYTOLOGY; DRUG COST; DRUG INDUSTRY; DRUG MANUFACTURE; ENGINEERING; FERMENTATION; HEALTH CARE; INSECT CELL; MAMMAL CELL; MANPOWER; NOTE; PRIORITY JOURNAL; RESEARCH;

BIOTECHNOLOGY; DRUG INDUSTRY; EMPLOYMENT; INTERNATIONALITY; MANUFACTURED MATERIALS; ORGANIZATIONAL CULTURE; OUTSOURCED SERVICES; PERSONNEL STAFFING AND SCHEDULING; PROFESSIONAL COMPETENCE; UNITED STATES;

INSECTA; MAMMALIA;

EID: 8344225300     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/nbt1104-1355     Document Type: Note

References (6)

1. Anscomb, A. Pharmaceutical outsourcing opportunities post launch. in Kalorama Information Market Intelligence (ed. Heffner, S.) (New York, 2004).
2. st Century. Bioprocess international Supplement Series (Bioprocess International, Eugene, OR, 2004).
3. Mallik, A. et al. in Mckinsey Quarterly 2002 Special Edition: Risk and Resilience. 9-11 (McKinsey, New York, 2002).
4. European Parliament and European Council. Off. J. Eur. Commun. L121, 34-44 (2001).
5. Usdin, S. BioCentury August 2, A1-A10 (2004).
6. Gross, A. Bioprocess International, 26-30 (2004).